Los Angeles Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Los Angeles Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.7K	Buy	+732	New	+$11.8K	﹤0.01%	1838
2023 Q3	–	Sell	-72,540	Closed	-$653K	–	1179
2023 Q2	$653K	Buy	+72,540	New	+$669K	﹤0.01%	768
2021 Q4	–	Sell	-18,229	Closed	-$318K	–	1434
2021 Q3	$318K	Sell	18,229 -1,850	-9%	-$37.5K	﹤0.01%	1287
2021 Q2	$481K	Buy	+20,079	New	+$525K	﹤0.01%	1183

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Los Angeles Capital Management's KALV Position: Q1 2026 in Review

Los Angeles Capital Management opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 732 shares worth $14.7K. The stake represents ﹤0.01% of the portfolio and ranks #1838 among its holdings. This is a return to the name: Los Angeles Capital Management previously reported a position in KALV as recently as Q2 2023.

Los Angeles Capital Management first reported a position in KALV in Q2 2021 and has held it in 4 quarters since. The position peaked at $653K in Q2 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Los Angeles Capital Management held 732 shares of KalVista Pharmaceuticals worth $14.7K as of Q1 2026.
KalVista Pharmaceuticals was a new Los Angeles Capital Management position in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1838 holding.
Los Angeles Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2021 and has held it in 4 quarters since.
Los Angeles Capital Management's KalVista Pharmaceuticals position peaked at $653K in Q2 2023.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.